Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/26/04	$1.210	-0.82%	3,62,983
03/26/03	$1.220	0.00%	2,03,326
02/26/02	$1.220	+1.67%	1,69,514
01/26/01	$1.200	-1.64%	3,85,397
31/26/31	$1.220	+1.67%	3,38,465

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.210USD

Average target price

4.000USD

Spread / Average Target

+230.58%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 01:30:00 05/09/2026 am IST			5-day change	1st Jan Change
1.210 ^USD	-0.82%		+0.83%	-48.07%

13/08	Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
13/08	Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	7.05Cr 6.06Cr 5.7Cr 5.21Cr 9.75Cr 665.29Cr 9.78Cr 67Cr 26Cr 341.34Cr 26Cr 26Cr 1.1TCr	P/E 2024	-0.81x	P/E 2025	15.5x
Enterprise Value	7.05Cr 6.06Cr 5.7Cr 5.21Cr 9.75Cr 665.29Cr 9.78Cr 67Cr 26Cr 341.34Cr 26Cr 26Cr 1.1TCr	EV / Sales 2024	11,70,430x	EV / Sales 2025	-
Free-Float	77.39%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	SPRO	Delayed
CBOE	SPRO	Real-time
Boerse Muenchen	2HA	Real-time
Tradegate	2HA	Real-time
Deutsche Boerse AG	2HA	Delayed
Börse Stuttgart	2HA	Delayed

13/08	Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
13/08	Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
27/07	Spero Therapeutics, Inc. Announces Appointment of Debra Jeske Zack as Chief Medical Officer	CI
15/07	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ
14/07	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody	CI
14/07	Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing	MT
14/07	Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion	RE
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Benchmark	CI
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Index	CI
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Index	CI
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index	CI
18/06	GSK says US FDA approves urinary tract infection treatment Utebzi	AN
17/06	GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections	CI

Spero Therapeutics, Inc. Share Price

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Valuation : Spero Therapeutics, Inc.

Chart: Spero Therapeutics, Inc.

Latest news : Spero Therapeutics, Inc.

Last Transcript : Spero Therapeutics, Inc.

Analysts' recommendations : Spero Therapeutics, Inc.

Press Releases : Spero Therapeutics, Inc.

News in other languages : Spero Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Spero Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

21/25/21	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
20/24/20	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
18/24/18	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
06/24/06	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
14/23/14	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT

04/09	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
03/09	Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference	AQ
13/08	Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update	AQ
07/08	Spero Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
06/08	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ

18/06	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
18/06	Star Warsh
18/06	MORNING BRIEFING - Deutschland/Europa -2-
17/06	GSK und Spero Therapeutics erhalten US-Zulassung für Utebzi
21/25/21	GSK et Spero publient des résultats positifs sur un antibiotique expérimental

1 day	-0.82%
1 week	+0.83%
Current month	-0.82%
1 month	-3.97%
3 months	-57.09%
6 months	-47.16%
Current year	-48.07%

1 week	1.18	1.24
1 month	1.18	1.3
Current year	1.08	3.08
1 year	1.08	3.08
3 years	0.51	3.22
5 years	0.51	19.87
10 years	0.51	23.64

Manager	Title	Age	Since
Esther Rajavelu CEO	Chief Executive Officer	47	10/01/2025
Debra Zack CTO	Chief Tech/Sci/R&D Officer	69	27/07/2026
Timothy Keutzer COO	Chief Operating Officer	58	01/02/2023

Director	Title	Age	Since
Milind Deshpande CHM	Chairman	69	01/01/2014
Patrick Volkert Vink BRD	Director/Board Member	62	01/09/2015
Frank Thomas CHM	Chairman	56	10/01/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
03/08/26	Debra Zack	Free	Chief Technology Officer	4,86,986	0.8411%
04/05/26	Esther Rajavelu	Sell	Chief Executive Officer	-25,240	0.0436%
06/02/26	Esther Rajavelu	Sell	Chief Executive Officer	87,917	0.1560%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPERO THERAPEUTICS, INC.	-0.82%	+0.83%	-43.72%	-15.38%	7.05Cr
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+88.96%	6.8TCr
ARGENX SE	-2.06%	-0.18%	+39.67%	+86.44%	6.49TCr
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+378.92%	2.76TCr
BIONTECH SE	+0.86%	+1.65%	-7.74%	-14.95%	2.61TCr
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+33.13%	+12.54%	2.57TCr
GENMAB A/S	-1.46%	+0.42%	+23.61%	-18.61%	2.01TCr
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+368.10%	1.72TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-6.60%	+531.89%	1.49TCr
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+164.98%	1.46TCr
Average	-1.32%	+0.31%	+34.06%	+158.29%	2.79TCr
Weighted average by Cap.	-1.52%	+0.18%	+38.35%	+137.31%

	2024	2025
Net sales	4.8Cr 4.13Cr 3.88Cr 3.55Cr 6.64Cr 452.98Cr 6.66Cr 46Cr 18Cr 232.41Cr 18Cr 18Cr 748.71Cr	6.68Cr 5.75Cr 5.41Cr 4.94Cr 9.24Cr 630.72Cr 9.27Cr 64Cr 25Cr 323.6Cr 25Cr 25Cr 1.04TCr
Net income	-6.86Cr -5.9Cr -5.55Cr -5.07Cr -9.49Cr -647.37Cr -9.51Cr -66Cr -25Cr -332.15Cr -26Cr -25Cr -1.07TCr	85.72L 73.76L 69.4L 63.4L 1.19Cr 81Cr 1.19Cr 8.2Cr 3.18Cr 42Cr 3.22Cr 3.15Cr 133.77Cr
Net Debt	-	-